DALLAS, Aug. 14, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Isis Pharmaceuticals (Nasdaq:ISIS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Isis Pharmaceuticals (Nasdaq:ISIS) should be of particular interest to biopharmaceutical companies: AVI Biopharmaceuticals Inc. (Nasdaq:AVII), Enzo Biochem Inc. (NYSE:ENZ), Genta Inc. (OTCBB:GETA) and Alnylam Pharmaceuticals Inc. (Nasdaq:ALNY).
It is available at: http://www.beaconequity.com/i/ISIS
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Isis Pharmaceuticals (ISIS) is an antisense drug development company focused upon providing direct route from genes to drugs to improve drug discovery productivity for the treatment of genetic disorders or infections. The Company licenses its antisense platform, a specially coded nucleic strands platform to bind to mRNA within human cells.
In the report, the analyst notes:
"The DNA/RNA market is expected to reach $1.2 billion by 2010, with antisense therapy technologies anticipated to generate nearly half the sales generated in 2010. This market's future growth is contingent upon the ability of DNA/RNA therapies to advance a significant number of drug therapies beyond phase III drug trials. The potential market is multi-billion as the technology becomes commercialized next year.
"The Company engages in a new class of pharmaceuticals with the potential of radically transforming methods of treating disease and conditions. The additional advantage of antisense technologies includes eliminating side-effects associated with protein or small-molecule pharmaceuticals dominating the industry. Antisense technologies target individual proteins, thereby raising patient satisfaction, as well. The powerful lure of antisense technologies to pharmaceutical companies is stark, as the delivery of antisense molecules to target specific RNA sequences shortens responses and predictability of intended results."
To read the entire report visit: http://www.beaconequity.com/i/ISIS
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions and information free of charge exclusively to individuals who wish to receive them.